Study Evaluating The Tolerability Of Multiple Doses Of HKI-272

Phase 1CompletedNCT00757809

Puma Biotechnology, Inc.50 enrolled

Overview

Study to investigate the occurence of diarrhea after either once daily or twice daily dosing for 14 days.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

HKI-272

Sex: ALLMin age: 18 YearsMax age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male and female (non-child bearing potential) subjects * Ages 18-50.

Unnamed facility

Austin, Texas, United States

Unnamed facility

Tacoma, Washington, United States

Occurence of diarrhea

Time frame: 14 days

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.